Parkinson's disease, dopaminergic drugs and the plant world

被引:10
|
作者
Kempster, Peter [1 ,2 ]
Ma, Andrew [1 ]
机构
[1] Monash Med Ctr, Neurosci Dept, Clayton, Vic, Australia
[2] Monash Univ, Sch Clin Sci Med, Clayton, Vic, Australia
关键词
Parkinson's disease; plants; dopamine; levodopa; phytochemicals; L-DOPA; LEVODOPA THERAPY; MUCUNA-PRURIENS; RESERPINE; APOMORPHINE; SEROTONIN; BROMOCRIPTINE; ACCUMULATION; PROLACTIN; REDUCTION;
D O I
10.3389/fphar.2022.970714
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A large proportion of drugs used for the treatment of neurological disorders relate to naturally occurring compounds, many of which are plant alkaloids. This is particularly true of Parkinson's disease (PD). The pharmacopoeia of PD has strong botanical origins, while major discoveries about the neurochemistry of the basal ganglia came from the study of phytochemicals. This article narrates the development of pharmacotherapy for PD in terms of historically important plant-derived substances & mdash;tropane and hamala alkaloids, reserpine, levodopa, apomorphine, and ergoline dopamine receptor agonists. Alkaloids are nitrogen-containing secondary metabolic products that tend to be biologically active. They appear to be involved in plants' adaptation to herbivorous animals, though their exact purpose and the ways in which they work are uncertain. A sizable group of alkaloids influence animal dopaminergic systems, highlighting a key biological relationship. While animals must acquire the energy that plants harness, plants need to engage with the animal attribute that they lack & mdash;movement & mdash;in order to maximize their reproductive fitness. Neuroactive flowering plant compounds have been interacting with vertebrate and invertebrate motor systems for 100 million years. A deep evolutionary connection helps to explain why the pharmacological treatment of PD is imprinted with the power of these mysterious botanical chemicals.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Dopaminergic drugs in development for Parkinson's disease
    Korczyn, AD
    PARKINSON'S DISEASE, 2003, 91 : 267 - 271
  • [2] Mirror movements in Parkinson's disease: effect of dopaminergic drugs
    Espay, A. J.
    Morgante, F.
    Gunraj, C.
    Chen, R.
    Lang, A. E.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2006, 77 (10): : 1194 - 1195
  • [3] Peripheral markers of apoptosis in Parkinson's disease the effect of Dopaminergic drugs
    Blandini, F
    Mangiagalli, A
    Cosentino, M
    Marino, M
    Samuele, A
    Rasini, E
    Fancellu, R
    Martignoni, E
    Riboldazzi, G
    Calandrella, D
    Frigo, GM
    Nappi, G
    APOPTOSIS: FROM SIGNALING PATHWAYS TO THERAPEUTIC TOOLS, 2003, 1010 : 675 - 678
  • [4] Influence of dopaminergic drugs on fatigue syndrome in patients with Parkinson's disease
    Datieva, V.
    Levin, O.
    JOURNAL OF NEUROLOGY, 2013, 260 : S144 - S145
  • [6] Dopaminergic drugs, paraphilic fantasies, paraphilic behaviours and creativity in Parkinson's disease
    Cannas, Antonino
    Solla, Paolo
    Floris, Gian Luca
    Serra, Claudia
    Costantino, Emanuela
    Piras, Valeria
    Marrosu, Francesco
    Marrosu, Maria Giovanna
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2010, 34 (03): : 563 - 564
  • [7] Acoustic voice analysis in patients with Parkinson's disease treated with dopaminergic drugs
    Gamboa, J
    JimenezJimenez, F
    Nieto, A
    Montojo, J
    OrtiPareja, M
    Molina, JA
    GarciaAlbea, E
    Cobeta, I
    JOURNAL OF VOICE, 1997, 11 (03) : 314 - 320
  • [8] Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease
    Steiger, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 (01) : 2 - 11
  • [10] Dopaminergic agonists in Parkinson's disease
    Alonso Canovas, A.
    Luquin Piudo, R.
    Garcia Ruiz-Espiga, P.
    Burguera, J. A.
    Campos Arillo, V.
    Castro, A.
    Linazasoro, G.
    Lopez del Val, J.
    Vela, L.
    Martinez Castrillo, J. C.
    NEUROLOGIA, 2014, 29 (04): : 230 - 241